Filing Details

Accession Number:
0001209191-22-059880
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-05 19:45:34
Reporting Period:
2022-12-01
Accepted Time:
2022-12-05 19:45:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750019 Tcr2 Therapeutics Inc. TCRR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1732986 Angela Justice C/O Tcr2 Therapeutics
100 Binney Street
Cambridge MA 02142
Chief People Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-01 59,576 $0.00 69,269 No 4 M Direct
Common Stock Disposition 2022-12-02 2,273 $1.39 66,996 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Acquisiton 2022-12-01 50,889 $0.00 50,889 $0.00
Common Stock Restricted Stock Unit Acquisiton 2022-12-01 2,840 $0.00 2,840 $0.00
Common Stock Restricted Stock Unit Acquisiton 2022-12-01 5,847 $0.00 5,847 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
13,527 No 4 M Direct
1,050 No 4 M Direct
6,336 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,693 Direct
Footnotes
  1. Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.
  2. Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
  3. The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
  4. 79% of these restricted stock units vested on December 1, 2022 and the remaining 21% will vest on December 1, 2023.
  5. 73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.
  6. 48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.